 |
News
-
High-Level Statement: Comprehensive approach for a treaty to end plastics pollution: Perspectives from the biopharmaceutical and consumer health industries (November 2024)
14 NOVEMBER 2024, GENEVA – We support a UN instrument to end plastics pollution through a harmonized, global approach that also prioritizes patient safety and safeguards access to medicinal and medical products.
Read More -
Global Biosimilars Week 2024 to Focus on Advancing Access to Biosimilars (November 2024)
In the week ahead, the International Generic and Biosimilar medicines Association (IGBA) will renew its commitment to raise awareness of the powerful and lifechanging impact of biosimilar medicines, and focus on the importance of advancing access to these essential therapies.
Read More -
AMIP, the Moroccan Pharmaceutical Industry Association, joins IGBA (September 2024)
IGBA, the International Generic and Biosimilar medicines Association, representing global manufacturers of generic and biosimilar medicines, announced today that AMIP has been accepted and welcomed as a new IGBA Associate Member.
Read More -
IGBA identifies streamlined development through reduced comparative clinical studies and appropriate use of global comparator product as key to greater biosimilar access (July 2024)
The mandate to conduct routine comparative clinical efficacy studies for biosimilar medicines, compounded by duplicative regional requirements, serves as a barrier to greater medicine access for patients. The International Generic and Biosimilar Medicines Association (IGBA) has issued two position papers;
… Read More -
IGBA Statement at the Opening of the Sessions at the WIPO Assemblies (July 2024)
Pharmaceutical innovation drives progress, and deserves reward, with intellectual property playing a key role in its protection. Expanding access to these innovations after rewarding them is crucial for public health. In well-functioning markets, generic and biosimilar medicines provide affordable, quality-assured
… Read More -
IGBA Welcomes update to ICH M7 on Assessment and Control of Nitrosamine Impurities (June 2024)
The International Generic and Biosimilar Medicines Association (IGBA) commends the General Assembly of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) for its decision to develop an Addendum to the ICH M7 Guideline on
… Read More -
IGBA Re-Elected to ICH Management Committee (June 2024)
The International Generic and Biosimilar Medicines Association (IGBA) welcomes the decision of the ICH General Assembly to re-elect the IGBA as a Management Committee Member of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH).
… Read More -
Joint Industry Statement for 77th World Health Assembly (May 2024)
Non-communicable diseases (NCDs) are on the rise and impacting the lives of people around the world. IGBA is pleased to join IFPMA, DITTA, GSCF, WHL, and PATH in a formal statement at WHA on the need for multistakeholder solutions to
… Read More -
IGBA’s CEO Advisory Committee advances strategic focus on access to medicines (May 2024)
Chief Executive Officers of the world’s largest generic and biosimilar medicines companies met in Vienna on 15 May 2024 to provide strategic advice to the International Generic and Biosimilar Medicines Association (IGBA). The generics and biosimilars sector, which supplies 70
… Read More -
IGBA Comments to the 13 March 2024 Proposal for negotiating text of the Pandemic Agreement (April 2024)
As the international representative organization of the generic and biosimilar medicines industry, IGBA joins the WHO and Member States in reaffirming the importance of multisectoral collaboration to safeguard human health and build stronger, more resilient health systems. In an open
… Read More -
Joint Industry Statement for WHO's Executive Board Meeting 154 (January 2024)
We welcome the Executive Board (EB) report on noncommunicable diseases (NCDs) and WHO’s continued efforts to tackle one of the greatest health challenges of our lifetimes. With childhood obesity and diabetes on an alarming rise, alongside population ageing, urbanization, climate
… Read More -
IGBA General Statement on WHO's Executive Board Meeting 154 (January 2024)
The International Generic and Biosimilar Medicines Association (IGBA), giving voice to the manufacturers of quality-assured, safe, and cost-effective generic and biosimilar medicines, welcomes the World Health Organization Executive Board’s focus on the Three Billion Targets in the EB154 agenda, linking
… Read More
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
Our Mission and Vision
Our vision is to promote the widest possible access to generic and biosimilar medicines with high quality, safety and efficacy, support international harmonized pathways for the registration of those medicines, and a strong commitment by members to standards agreed by the International Council for Harmonization (ICH) and WHO accredited regulators.
Introduction
In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.
The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. To reflect the evolving nature of the industry, in September 2015, IGPA incorporated under Swiss Law, and at the same time changed the name of the organization to the International Generic and Biosimilar Medicines Association (IGBA).
